TherOx has developed a proprietary medical technology called SuperSaturated Oxygen (SSO2) Therapy. SSO2 Therapy creates a highly-oxygenated saline solution and combines it with the patient’s arterial blood to provide focal hyperbaric oxygen therapy to ischemic (oxygen deprived) tissues. The initial focus of SSO2 Therapy is for the treatment of acute myocardial infarction (heart attack), with additional future clinical efforts envisioned for stroke, oncology, and other physiologic applications.

TherOx holds 20 issued patents and continues to expand its intellectual property portfolio related to additional methods and systems for preparation and delivery of oxygen to targeted areas of the body.


Current standard of care for the most severe heart attacks involves mechanically opening the blocked artery using percutaneous coronary intervention (PCI), otherwise known as angioplasty and stenting. While PCI has reduced early mortality post-heart attack over the past 25 years, significant myocardial tissue (heart muscle) death and sizable scarring may be present even after the left anterior descending (LAD) artery has been stented. This myocardial damage is linked to increased risk of heart failure and long-term mortality2.

SSO2Therapy is a novel treatment that complements PCI and is designed to minimize myocardial damage caused by acute myocardial infarction in qualifying patients suffering a LAD ST-elevation myocardial infarction (STEMI) event who are treated with primary PCI within 6 hours of symptom onset. SSO2 Therapy delivers superoxygenated arterial blood directly to at-risk myocardial tissue and is performed in the cardiac catheterization laboratory immediately after PCI is completed.

SSO2 Therapy has been clinically evaluated in several studies. Learn more about the clinical results here.

2 Stone GW, et al. Relationship between infarct size and outcomes following primary PCI. JACC 2016;67(14):1674-83.
3 Stone GW, et al. Effect of Supersaturated Oxygen Delivery on Infarct Size after Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circ Cardiovasc Intervent. 2009;2:366-75.

Caution: Federal (United States) law restricts this device to sale by or on the order of a physician.
The TherOx DownStream System is indicated for the preparation and delivery of SuperSaturated Oxygen Therapy (SSO2 Therapy) to targeted ischemic regions perfused by the patient’s left anterior descending coronary artery immediately following revascularization by means of percutaneous coronary intervention (PCI) with stenting that has been completed within 6 hours after the onset of anterior acute myocardial infarction (AMI) symptoms caused by a left anterior descending artery infarct lesion.